Granules India Q2 FY24 PAT drops 30% at Rs. 102 Cr

Sales in the US region grew well, partially offset by the decline in the LATAM and European regions

Glenmark Pharma reports Q2 FY24 loss at Rs. 62 Cr

European operations' revenue grew 58.4% to Rs 599.7 crore

Marksans Pharma posts Q2 FY24 consolidated PAT at Rs. 82.7 Cr

US business grew by +12.8% YoY

GSK registers 5% revenue growth in Q2 FY24

General Medicine grows 5% and Vaccines 10% led by Shingrix

SMS Pharmaceuticals reports robust Q2FY24 operational performance

Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore

Aurobindo Pharma posts Q2 FY 24 up 84% at Rs. 752 Cr

The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23

Bayer posts Q3 2023 Group sales Euro 10.34 billion

We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”

Supriya Lifescience reports Q2 FY24 PAT higher 42% at Rs. 23.88 Cr

Morepen Laboratories posts Q2 FY24 consolidated PAT at Rs. 21.25 Cr

Morepen Laboratories has reported total income of Rs. 425 crores during the quarter ended September 30, 2023

Dr Lal Path Labs posts Q2 FY24 consolidated PAT at Rs. 109.3 Cr

Dr. Lal Path Labs has reported total income of Rs. 619.4 crores during the period ended September 30, 2023